Non-completion of changes to prescribed medications in people with Parkinson's disease.

1. Masuda Y. Cardiac effects of cholinesterase inhibitors used in Alzheimer’s disease-from basic research to the bedside. Curr Alzheimer Res 2004; 1: 315–21. 2. Ballard CG, Shaw F, McKeith I, Kenny R. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 1998; 51: 1760–2. 3. Ballard CG, Shaw F, Lowery K, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer’s Disease. Dement Geriatr Cogn Disord 1999; 15: 97–103. 4. Hyattsville MD. Current estimates from the National Interview Survey, 1995. National Centre for Health Statistics. Vital Health Statistics 1998, Series 10 (No. 199). US Department of Health and Human Services, Centres for Disease Control and Prevention, National Centre for Health Statistics. 5. Hay L, Grossberg GT. Polypharmacy in the elderly: clinical implications. Int J Geriatr Psychopharmacol 1998; 1: S15–9. 6. Gill SS, Bronskill SE, Mamdani M et al. Representation of patients with dementia in clinical trials of Donepezil. Can J Clin Pharmacol 2004; 11: 274–85. 7. Pfizer Laboratories Ltd. Accept data sheet, 26 February 2003. http://www.medsafe.govt.nz/profs/Datasheet/a/ Aricepttab.htm (Last accessed 20 February 2007). 8. http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid=16219#CLINICAL PRECAUTIONS, (Last accessed 20 February 2007). 9. FDA Alert [3/2005]: alert for healthcare professionals on Galantamine hydrochloride (marketed as Razadyne, formerly Reminyl). http://www.fda.gov/cder/drug/InfoSheets/HCP/ galantaminelHCP.htm (last accessed 20 February 2007). 10. http://www.bnf.org/bnf/bnf/52/61148.htm?q=% 22donepezil%22 (last accessed 20 February 2007).